Revision of Chapter 7 Contract Manufacture and Analysis
|
|
- Diane Newman
- 6 years ago
- Views:
Transcription
1 Revision of Chapter 7 Contract Manufacture and Analysis GMP & Market Compliance Information Day, Catherine Neary Inspector Date Insert on Master Slide Slide 1
2 Overview Purpose of revision to Chapter 7 Comparison of ICH & EU GMP Requirements Impact Assessment & Implications of new revision Next Steps 14 October 2010 Slide 2
3 Revision of Chapter 7 EU GMP (1) Contract Manufacture & Analysis EMA concept paper published in October edural_guideline/2009/10/wc pdf Draft revision at the finalisation stage Public consultation before end 2010 Watch for further details 14 October 2010 Slide 3
4 Revision of Chapter 7 EU GMP (2) Purpose of the Revision Reflect the range & extent of modern contracting operations Reflect the increased complexity in modern contracted arrangements Harmonisation with ICH Q10 More prescriptive requirements for outsourced operations Particular emphasis on the contract giver s obligations 14 October 2010 Slide 4
5 ICH Q10 ICH Guidelines can be accessed through the following link: ICH Q10 Pharmaceutical Quality System Guidance on key elements for an effective quality system Complements ICH Q8 Pharmaceutical Development & ICH Q9 Quality Risk Management ICH Q10 (Section 2.7): Management of Outsourced Activities & Purchased Materials 14 October 2010 Slide 5
6 Comparison of ICH & EU GMP Requirements ICH Q10 EU GMP Chapter 7 Applies to all outsourced activities & purchased materials Obligations specific to the Contract Giver Assessment should incorporate QRM principles Specific in the need for prior assessment & audit Requires both responsibilities & communication processes to be defined in contract Specific in the need for periodic review of contract acceptor Applies only to contract manufacture and analysis Includes obligations for the contract giver & contract acceptor Not specific to use of QRM Not specific to the need for prior assessment or audit Requires responsibilities to be defined in contract Not specific in terms of requirement for periodic review 14 October 2010 Slide 6
7 Main Principles of ICH Q10 Prior Assessment of the contract acceptor Definition of responsibilities & communication methods Ingredient & material monitoring Monitoring & Review measures 14 October 2010 Slide 7
8 Impact Assessment of Revision to Chapter 7 Additional regulatory burden should be light Technical arrangements for outsourced GMP activities more transparent Clearer & more consistent assessment of outsourced activities Set clearer standards & expectations for industry Harmonised regulatory policy 14 October 2010 Slide 8
9 Implications of Revision to Chapter 7 Extends the range of contracted activities to which Chapter 7 applies Examples of Activities to consider Qualification & Validation Activities QP & Other Professional Services Maintenance & Calibration of Equipment & Premises Storage & archiving 14 October 2010 Slide 9
10 Implications of Revision to Chapter 7 Inclusion of requirements for control over subcontracted operations Mutual Agreement Assessment & On-going Review Contract Giver Prior Assessment Legality Suitability Competence Contract Acceptor On-going Review Records Results Subcontractor Subcontractor 14 October 2010 Slide 10
11 Implications of Revision to Chapter 7 Inclusion of New Requirements for the Contract Communication Processes Subcontracted activities Audit requirement as opposed to visit 14 October 2010 Slide 11
12 Next Steps Review updates Public Consultation before end 2010 GAP Analysis Prepare Strategy Implement Change Points to Consider:- Outsourced Activities not covered under the vendor approval system Review of subcontracting arrangements Review of contracts Points to Consider:- Outsourced Activities not covered under the vendor approval system Review of subcontracting arrangements Prior assessment & Audit obligations Contracts Points to Consider:- Use of change control to implement the strategy 14 October 2010 Slide 12
13 In Summary Current vs. Proposed Contract Manufacture & Analysis Contract Acceptor Outsourced Activities Contract Acceptor & subcontractors Visit Audit 14 October 2010 Slide 13
GMP Track 1 Day 2 Session 1 Vendor Assurance
GMP Track 1 Day 2 Session 1 Vendor Assurance 11 August 2015 150403_POUT This session Three presentations Chapter 6 and 7 - Trevor Schoerie Quality Control Out sourced Activities Draft - FDA Quality Metrics
More informationOutsourcing - managing risks and opportunities over which you now have less control
Outsourcing - managing risks and opportunities over which you now have less control Kevin O Donnell, PhD PDA Meeting, Dublin 22 nd November 2018 Slide 2 Typical Examples The key GMP Requirements & Guidance
More informationRegulatory Update. Paul Sexton. QP Forum
Regulatory Update Paul Sexton QP Forum 16 th April, 2015 Content Updates on GMP Guidance Updates on EU Legislation Draft Ph Eur monograph on WFI including RO 2 Chapter 5 - Production Paragraphs 27 to 30
More informationPharmaceutical Quality System (PQS)
Implementation of ICH Q8, Q9, Q10 Pharmaceutical Quality System (PQS) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Structure of
More informationEuropean Union (EU) Regulatory Trends in GMP. Clive Brading Tianjin, China September 23, 2009
European Union (EU) Regulatory Trends in GMP Clive Brading Tianjin, China September 23, 2009 -2- Presentation Topics EU Background Inspections outside the EU EMEA Inspection Outcomes Dedicated Facilities
More informationMaterials Management Traceability, CEPs and managing non-conforming sites
Materials Management Traceability, CEPs and managing non-conforming sites IMB Information Day, 14 th October 2010 Dr Cormac Dalton Inspector 13-Oct-10 Slide 1 Managing Supply Supply Demand Supply chain
More informationQuality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals
Quality Agreements with CMO s Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals FDA Guidance Contract Manufacturing Arrangements for Drugs: Quality
More informationThe APIC Audit Programme Version 5, July 2017
The APIC Audit Programme Version 5, July 2017 Table of contents 1 General 2. APIC Audit Programme 3 The Auditors 3.1 Educational Background and Experience 3.2 Auditor Training Courses for Certification
More informationImpacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario
Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Innovacion en Packaging Primario 1 Contents Company Highlight What s Changing in Pharma Pharma Trends Harmonisation New Requirements
More informationQuality Risk Management
Implementation of ICH Q8, Q9, Q10 Quality Risk Management International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Introduction Structure of
More informationICH Quality Implementation Working Group POINTS TO CONSIDER
ICH Quality Implementation Working Group POINTS TO CONSIDER ICH-Endorsed Guide for ICH Q8/Q9/Q10 Implementation Document date: 16 June 2011 International Conference on Harmonisation of Technical Requirements
More informationRegulatory Requirements & Recent Changes, including expectations for APIs & IMPs
Regulatory Requirements & Recent Changes, including expectations for APIs & IMPs Neil Raw - GMP Inspector Richard Andrews - Operations Manager 11 th November 2008 Programme: Regulatory Requirements Neil
More informationQUALITY ASSURANCE. Pharma Quality Agreements: What Are They, and Why They Matter For Your Study ABSTRACT
WHITE PAPER PRESENTED BY PREMIER RESEARCH Pharma Quality Agreements: What Are They, and Why They Matter For Your Study ABSTRACT Quality Agreements are an effective bridge to a successful future for companies
More informationThe APIC Audit Programme Version 3, August 2010
The APIC Audit Programme Version 3, August 2010 Table of contents 1 General 2. APIC Audit Program 3 The Auditors 3.1 Educational Background and Experience 3.2 Auditor Training Courses for Certification
More informationWholesaling & Distribution & the GMPs
Wholesaling & Distribution & the GMPs Presented by Bryan Wright 11 th July 2016 Overview Wholesaling & distribution of Medicines (FPs) in the EU New EU GDP Guidelines Expectations How complicated can the
More informationWholesaling & Distribution & the GMPs
Wholesaling & Distribution & the GMPs Presented by Bryan Wright 11 th July 2016 Overview Wholesaling & distribution of Medicines (FPs) in the EU New EU GDP Guidelines Expectations How complicated can the
More informationSTANDARD OPERATING PROCEDURE
Lab. Ofichem B.V. Pag.: 1 / 14 Contents 1. General... 2 2. Scope... 3 3. Definitions and abbreviations... 3 4. Shared Third Party audit program... 3 5. Reassurance absence of Conflict of Interest... 5
More informationNew GMPs for Active Substances & Excipients. Presented by Eoin Hanley 4 July, 2016
New GMPs for Active Substances & Excipients Presented by Eoin Hanley 4 July, 2016 What we will cover in this session The changing landscape EC Guideline on principles of GDP of active substances Formalised
More informationTrinity College Dublin QP Forum 2017 Tuesday 25 th April
Trinity College Dublin QP Forum 2017 Tuesday 25 th April HPRA QUESTIONS & ANSWERS 1. What is the approach being taken for audit of contamination control strategies as per chapters 3 & 5? What is the current
More information1201 Maryland Avenue SW, Suite 900, Washington, DC ,
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org 15 July 2010 European Commission Enterprise and Industry Directorate General Consumer Goods, Pharmaceuticals B-1049 Brussels
More informationEU and FDA GMP Regulations: Overview and Comparison
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational
More informationQuality Assessment & GMP Similarities & Differences
Quality Assessment & GMP Similarities & Differences EMEA, Monday 26 th October 2009 Cormac Dalton Inspector Irish Medicines Board Date 12-Oct-09 Slide 1 Content Overview of commonalities & differences
More informationWorking Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice
Version 8 (final) EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 Working
More informationRegional GMP Strengthening Workshop for Indian Pharmaceutical Manufacturers and State Regulators
Regional GMP Strengthening Workshop for Indian Pharmaceutical Manufacturers and State Regulators Focused on GMP in production of Active Pharmaceutical Ingredients and Oral Solid Dosage Forms Organized
More informationEurope s new approach to assurance of API quality and its implications for manufacturers and producing countries
Europe s new approach to assurance of API quality and its implications for manufacturers and producing countries IPA / EDQM / WHO Mumbai Conference 28 September 2012 Dr Florence Benoit-Guyod, EDQM Inspector,
More informationVergleich der Versionen von Kapitel 7 des EU-GMP-Leitfadens (September 2012)
(Valid until January 31, Principle Contract manufacture and analysis must be correctly defined, agreed and controlled in order to avoid misunderstandings which could result in a product or work of unsatisfactory
More informationQuality Risk Management. of the GDP Supply Chain. Dr Cormac Dalton Inspector. Crowne Plaza Hotel, 25/2/2010. Date 22-Feb-10 Slide 1
Quality Risk Management of the GDP Supply Chain Crowne Plaza Hotel, 25/2/2010 Dr Cormac Dalton Inspector Date 22-Feb-10 Slide 1 Supply Chain Experiment Pharmaceutical excipient ordered 3 rd December 09
More informationRegulatory Update. Greg McGurk, GMP Manager (acting) GMP Conference. 7 February 2017 Dublin
Regulatory Update Greg McGurk, GMP Manager (acting) GMP Conference 7 February 2017 Dublin GMP Update Chapter 3 - Premises and Equipment (into operation since 1 March 2015) Chapter 5 - Production (into
More informationCost-effective Purification of Vaccines, Data Integrity Systems and CTDs. DRAFT AGENDA Rio de Janeiro, 18 to 20 June 2018
Cost-effective Purification of Vaccines, Data Integrity Systems and CTDs DRAFT AGENDA Rio de Janeiro, 18 to 20 June 2018 DAY1, Monday 18 June - Welcome & Introduction Plenary session for all participants
More informationGMP GUIDELINES. GMP Guides from Industry Organisations. FDA cgmp WHO GMP. cgmp Guide Drugs 21 CFR 210 GAMP. ISPE Technical Guides
FDA cgmp cgmp Guide Drugs 21 CFR 210 cgmp Guide Drugs 21 CFR 211 cgmp Guide Medical Device 21 CFR 808, 812, 820 cgmp Guide Biologics 21 CFR 600, 606, 610 Guideline List Human Drugs Guideline List Biologics
More informationSupersedes Division Name Revision No. 0 Export Division Page No. 1 of 9
Page No. 1 of 9 Control Status 1.0 Purpose To lay down a procedure for conducting GMP inspection and report writing for issue of Written Confirmation for for medicinal products for human. 2.0 Scope This
More informationGMP for ATMP. Advanced Therapy Medicinal Products Key2Compliance AB
GMP for ATMP Advanced Therapy Medicinal Products 2018 Key2Compliance AB 1 Content Background and regualtory requirements GMP Walkthrough Quality Risk Management 2018 Key2Compliance AB 2 Background and
More informationLegislative Framework and Scientific Guidance in European Assessment
Legislative Framework and Scientific Guidance in European Assessment Riccardo Luigetti Quality Assessors Training London 26 October 2009 1 Content of the presentation Scientific guidelines Other related
More informationGUIDELINES ON THE PRINCIPLES OF GOOD DISTRIBUTION PRACTICE OF ACTIVE SUBSTANCES FOR MEDICINAL PRODUCTS FOR HUMAN USE
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 047-1 Annex 1 July 2018 GUIDELINES ON THE PRINCIPLES OF GOOD DISTRIBUTION PRACTICE OF ACTIVE SUBSTANCES FOR MEDICINAL
More informationWork plan for the GMP/GDP Inspectors Working Group for 2017
13 January 2017 EMA/INS/GMP/584202/2016 Work plan for the GMP/GDP Inspectors Working Group for 2017 Chairperson: David Cockburn Adopted: December 2016 1. Meetings scheduled for 2017 Face-to-face meetings
More informationAnnex 14 WHO guidelines for drafting a site master file 136
World Health Organization WHO Technical Report Series, No.961, 2011 Annex 14 WHO guidelines for drafting a site master file 136 1. Introduction 2. Purpose 3. Scope 4. Content of site master fi le Appendix
More informationChristian Gausepohl, Frank Böttcher. GMP Focus. Managing Contract Manufacturers and Testing Labs. PDF Download. Excerpt from the GMP MANUAL
Christian Gausepohl, Frank Böttcher GMP Focus Managing Contract Manufacturers and Testing Labs PDF Download Excerpt from the GMP MANUAL Bibliographic Data of the Deutsche Nationalbibliothek: http://dnb.ddb.de
More informationImpact of EU GMPs on Australian GMP. Trevor Schoerie PharmOut
Impact of EU GMPs on Australian GMP Trevor Schoerie PharmOut Part I Basic Requirements for Medicinal Products Current TGA Version, 7 years out of date TGA are actively and publically talking about PE009-0813
More informationGood Distribution Practice and Supply Chain Risk Evaluation
Good Distribution Practice and Supply Chain Risk Evaluation Who we are - Exelsius An international consultancy established in 2007 bringing cross-sector expertise and skills into a range of services designed
More informationWork plan for the GMP/GDP Inspectors Working Group for 2018
30 November 2017 EMA/INS/GMP/504401/2017 Inspections, Human Medicines Pharmacovigilance & Committees Division Work plan for the GMP/GDP Inspectors Working Group for 2018 Chairperson: Brendan Cuddy Adopted:
More informationImpacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales
Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Empaques Primarios y Tendencias Farmaceuticas para Inyectables 1 International Support Support in R&D Technology Transfer
More informationEvaluation of Counterfeit Cases Impact of FMD & GDPs. Lorraine Nolan Healthcare Products Distribution Manager
Evaluation of Counterfeit Cases Impact of FMD & GDPs Wholesale Distribution Information Day, 28th September 2012 Lorraine Nolan Healthcare Products Distribution Manager Slide 1 Contents 1. Review of UK
More informationEffective Management and Operations of GXP Laboratories
Effective Management and Operations of GXP Laboratories Course Objective: Upon completion of this course, attendees involved in establishing and assuring that Good Laboratory / Good Manufacturing Practice
More informationGood Manufacturing Practice for ATMPs Rocio Salvador Roldan DG SANTE, Unit B5
Good Manufacturing Practice for ATMPs Rocio Salvador Roldan DG SANTE, Unit B5 This presentation only reflects the views of its author and does not necessarily reflect the opinion of the Commission Overview
More informationLatino America Consultores Innovation & Technology to make your Business Compliant
Latino America Consultores Innovation & Technology to make your Business Compliant Annex 15 & EMA Process Validation Guide Line 1 Changes in Requirements The Pharmaceutical Industry has adapted its business
More informationCold Chain Committee Guidance for shippers, transport service providers and subcontractors
Guidance for shippers, transport service providers and subcontractors involved in the distribution of pharmaceutical products registered for storage between 2 and 8 Celsius Guidance for Shippers 1 of 7
More informationTextvergleich. Verglichene Dokumente MEDIA3917.pdf. ICH_Q10_Step4.pdf
Textvergleich Verglichene Dokumente MEDIA3917.pdf ICH_Q10_Step4.pdf Übersicht 2270 Wort/Wörter hinzugefügt 1338 Wort/Wörter gelöscht 3558 Wort/Wörter übereinstimmend 157 Block/Blöcke übereinstimmend Blättern
More informationGMP for ATMPs. Ian Rees, Unit Manager Inspectorate Strategy & Innovation 4 th October 2018
GMP for ATMPs Ian Rees, Unit Manager Inspectorate Strategy & Innovation 4 th October 2018 Presentation outline MHRA Annex 2-2013 Change procedure for GMP guidelines Part IV EU & PIC/S MHRA/BP/NIBSC - standards
More information" NATIONALLY AND INTERNATIONALLY AT THE HIGHEST LEVEL." Audit
" NATIONALLY AND INTERNATIONALLY AT THE HIGHEST LEVEL." Audit " NATIONALLY AND INTERNATIONALLY AT THE HIGHEST LEVEL." pharmaplace AG EXPLOITING POTENTIALS TOGETHER " Since 2009, we have had GMP audits
More informationAdvantages, Opportunities & Challenges of Adopting the Post Approval Change Management Plan (PACMP)
Advantages, Opportunities & Challenges of Adopting the Post Approval Change Management Plan (PACMP) Quality Forum September 2018 roger nosal, Vice President & Head Worldwide Safety & Regulatory - Global
More informationPHARMA KNOWLEDGE PARK
GUIDELINES 2013 WWW.NOORMD.COM A COMPILATION BY ON PHARMACEUTICAL REGULATORY GUIDELINES INTRODUCED / REVISED DURING THE YEAR 2013. Page 2 ICH Assessment and control of DNA reactive (mutagenic) impurities
More informationChristine Oechslein. GMP Focus. Managing Process Validation. A Drugmaker s Guide. PDF Download. Excerpt from the GMP MANUAL
Christine Oechslein GMP Focus Managing Process Validation A Drugmaker s Guide PDF Download Excerpt from the GMP MANUAL Bibliographic Data of the Deutsche Nationalbibliothek: http://dnb.ddb.de ISBN: 978-3-95807-056-1
More informationElectronic Systems - Regulators Observations
Electronic Systems - Regulators Observations Catherine Neary QP Forum Trinity College Dublin, 16 th April 2015 Agenda Introduction to Topic Data Integrity Considerations for any Electronic System Summary
More informationGood Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations
Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations 9th edition of Synevo Clinical Research Symposium. 17 th November 2017 Bucharest.
More informationLessons from Pharmaceutical Laboratory related FDA Warning Letters
Lessons from Pharmaceutical Laboratory related FDA Warning Letters The Agilent Critical Compliance Seminar 2016 Ludwig Huber Ludwig_huber@labcompliance.com Overview FDA Inspections and reports GMP compliance
More informationDECEMBER 2008 GUIDANCE NOTES ON PRODUCT QUALITY REVIEW
DECEMBER 2008 GUIDANCE NOTES ON PRODUCT QUALITY REVIEW 1.0 INTRODUCTION: The purpose of this guidance is to communicate the expectation with regard to the conduct of Product Quality Review. Product Quality
More informationCommon deficiencies/ hot topics
Common deficiencies/ hot topics Non-sterile & API manufacture Oisín Daly GMP Conference 7 February 2017 Dublin Non-sterile finished product manufacture Deficiencies by Eudralex Vol. 4 GMP guide > 60% 3
More informationInternational Supply Chain: How are we handling globalisation? GCP oversight
International Supply Chain: How are we handling globalisation? GCP oversight Susana Almeida, PhD Senior Director, European Operations Inflamax Research (Canada) patients quality value sustainability partnership
More informationFDA Quality Metrics, Data Integrity and Application of Statistics Throughout Process Validation in a Global Economy
CBI Statistics in Validation FDA Quality Metrics, Data Integrity and Application of Statistics Throughout Process Validation in a Global Economy Jerry Lanese Ph.D. The Lanese Group, Inc. 2017 The Lanese
More informationInspection of API Manufacturers & Update on Registration Process
Inspection of API Manufacturers & Update on Registration Process Catherine Neary, GMP Inspector GMP Conference 7 February 2017 Dublin Presentation Contents HPRA Inspection Programme for API Manufacturers
More informationNew EU GMP for ATMPs vs existing GMPs pros and cons. Drew Hope Director of Quality Operations, Autolus
New EU GMP for ATMPs vs existing GMPs pros and cons Drew Hope Director of Quality Operations, Autolus Rapid implementation The EC adopted GMP requirements for ATMPs 22 NOV 2017 Comes into operation 22
More informationExcipient Certification Scheme
Excipient Certification Scheme CPhI Breakfast Briefings Feria de Madrid, 13 th October 2009 Dr Arnulf Heubner Member of the EFCG-Board and Chairman of the Pharmaceutical Business Committee (PBC) Excipient
More informationStandard Operating Procedure. Vendor Management
REFERENCE: VERSION NUMBER: 2.0 EFFECTIVE DATE: 28-03-18 REVIEW DATE: 28-03-20 AUTHOR: Clinical Trials Manager, Contracts & Quality Management Officer REVIEWED BY: Research & Innovation Group APPROVED BY:
More informationUnderstanding the requirements of EU food contact legislation
Understanding the requirements of EU food contact legislation Dr. Annette Schäfer Head of Sector Food Contact Materials DG SANCO The content of this lecture does not necessarily represent the position
More informationExcipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance
Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance by Tom Savage, NSF International Since 2008, when patient deaths were first linked to
More informationQuality Risk Management (QRM) of active pharmaceutical ingredients during transportation by using FMEA tools and methodology
PharmaTutor PRINT ISSN: 294-6679 E-ISSN: 247-788 2 Quality Risk Management (QRM) of active pharmaceutical ingredients during transportation by using FMEA tools and methodology Upendra Kumar Singh*, Sammer
More informationGDP for APIs New Regulations. we prove it. The Shift to Monitoring BioPharma Product Quality Throughout Their Lifecycle
1 - Temperature Control Challenges - Full Lifecycle Monitoring WHITE PAPER GDP for APIs New Regulations The Shift to Monitoring BioPharma Product Quality Throughout Their Lifecycle we prove it. 2 GDP for
More informationQS, GDP (+GMP?) Maintaining the Integrity of The Supply Chain
QS, GDP (+GMP?) Maintaining the Integrity of The Supply Chain Presented by: Karen Ginsbury For IFF 01 March, 2017 Pharma Supply Chain Manufacturer Wholesaler Raw Material Supply Production Transport Warehouse
More informationGood Distribution Practices Toolkit Change Control 10 March 2016
Good Distribution Practices Toolkit Change Control 10 March 2016 1 Disclaimer The content of this presentation were derived mainly from WHO training material on Change Control and edited to suit the Distributor
More informationLEGAL REQUIREMENTS and DATA INTEGRITY...
LEGAL REQUIREMENTS and DATA INTEGRITY... 1 1 DI Guidances MHRA GMP DI Definitions & Guidance for Industry, March 2015 Guidance on Good Data & Record Management, March, 2016 Data Integrity and Compliance
More informationRisk Based Validation. Why, How and with what tools?
Risk Based Validation Why, How and with what tools? Tech Talk Agenda History of FDA GMP initiative for the 21 st Century. Industry response to FDA initiative. Harmonisation through ICH. ASTM Standard on
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 3 19 June 2012 EMA/119871/2012 4 5 Guideline on good pharmacovigilance practices (GVP) Module III Pharmacovigilance inspections Draft finalised by the Agency in collaboration with Member States and
More informationRegulations and guidance for the pharmaceutical industry
w w w. spec troscopyonline. com April 2011 Spectroscopy 26(4) 1 Focus on Quality Is GMP Annex 11 Europe s Answer to 21 CFR 11? January 2011 saw the publication of the new revision of European Union (EU)
More informationQualified Persons in the Pharmaceutical Industry. Code of Practice. March 2008
Qualified Persons in the Pharmaceutical Industry Code of Practice March 2008 Updated October 2009 Code of Practice for Qualified Persons 1. INTRODUCTION... 1 2. REGULATORY BASIS FOR THE QUALIFIED PERSON...
More informationQuality Risk Management: Excipients
Quality Risk Management: Excipients ExcipientFest 2012 Presented by: Londa Ritchey, M.S. Director, Supplier Qualification Global Quality Operations Pfizer, Inc. Agenda Regulatory Environment Material Quality
More informationHetero Drugs Limited
Global Challenges in Quality Assurance of APIs The Perspective of Indian Manufacturers Slide 1 of 30 1 Slide 2 of 30 2 Laws Governing GMPs/Quality United States Food, Drugs and Cosmetics Act Europe European
More informationEMA perspective on Quality Metrics
EMA perspective on Quality Metrics Indian Pharmaceutical Alliance Annual Congress, Mumbai India Presented by Brendan Cuddy on 24 February 2017 Head of Manufacturing and Quality Compliance, European Medicines
More informationSession 4: Quality Defect Investigations and Product Recalls
Session 4: Quality Defect Investigations and Product Recalls Amy Kelly Ph.D. and Kevin O Donnell Ph.D. GMP Conference 12 th November 2014 Outline The application of QRM principles to QD investigations
More informationPharmaceutical quality requirements
Pharmaceutical quality requirements through development to commercial medicinal product December 4, 2014 Karin Walhagen Biomedicine the Profession Biomedicine Master Program at Lund University Patient
More informationPHARMACEUTICAL COMMITTEE SUMMARY RECORD 60 th meeting, 2 nd May 2006
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals PHARM 529 PHARMACEUTICAL COMMITTEE SUMMARY RECORD 60 th meeting, 2 nd May 2006 OPENING Mr Martin Terberger,
More informationQP s experience with QRM. Fergus O Connell QA Manager AMS Laboratories
QP s experience with QRM Fergus O Connell QA Manager AMS Laboratories December 2011 Risk Management in a QPs role Validation Master Plan Risk Review Early issues Human Error Risk Influencing Factors EU
More informationInspection. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Outline Aim of - as a key part of the regulatory
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationThe European Commission's Proposal to Re-design Existing European Drug Safety Rules. An Industry View on Practical Implications
The European Commission's Proposal to Re-design Existing European Drug Safety Rules An Industry View on Practical Implications Margaret Walters Merck, Sharp & Dohme Ltd. The Second International Pharmaceutical
More informationChallenges in Implementing Knowledge Management within ICH Q10
Challenges in Implementing Knowledge Management within ICH Q10 SYMPOSIUM - New Frontiers in Manufacturing Technology, Regulatory - Brasilia Joseph C. Famulare Vice President, Global Head Compliance and
More informationAPI Inspections in Emerging Markets: The EDQM Experience
API Inspections in Emerging Markets: The EDQM Experience 18 October 2010 Sträter Life Science Gründungsymposium Dr Florence Benoit-Guyod, EDQM Inspector Certification of Substances Division European Directorate
More informationGood Manufacturing Practices Purpose and Principles of GMP. Tony Gould
Good Manufacturing Practices Purpose and Principles of GMP Tony Gould Why GMP? Provides a high level assurance that medicines are manufactured in a way that ensures their safety, efficacy and quality Medicines
More informationQUALITY AGREEMENT. The following Agreement has been concluded between
QUALITY AGREEMENT The following Agreement has been concluded between LLC LABORATORIES The contract laboratory and service provider 1625 Trinity Dr., Unit 11 Mississauga, Ontario Canada L5T 1W9 Hereinafter
More informationCDER Perspective: Good Clinical Practice
CDER Perspective: Good Clinical Practice Sensible Guidelines Symposium, 25 May 2012 Ann Meeker-O Connell FDA, CDER, Office of Compliance Office of Scientific Investigations The views presented in this
More informationRe: PCIM/11/01 Public Consultation on Implementing Measures for Pharmacovigilance
07 November 2011 By email: sanco pharmaceuticals@ec.europa.eu Directorate General for Health and Consumers Unit SANCO/D/3 BE 1049 Brussels Belgium Dear Sirs, Re: PCIM/11/01 Public Consultation on Implementing
More informationGMP for ATMP should be a document annexed to standard GMP (a new Annex) and not a stand-alone document.
Leem comments on Commission proposal for Good Manufacturing Practice for Advanced Therapy Medicinal Products 1. General comments Line number(s) of the relevant text General comment
More informationTask, View and Values
Task, View and Values TASK VIEW VALUES We help to analyze, improve and validate the key business processes of our clients, through our own methodology, so we can guarantee the quality, the efficiency and
More informationCurrent Global GMP Status and Trends With Focus on EU & PIC/S JPMA Annual Meeting, Tokyo & Osaka, September 2012 Dr.-Ing.
Current Global GMP Status and Trends With Focus on EU & PIC/S JPMA Annual Meeting, Tokyo & Osaka, September 2012 Dr.-Ing. Stephan Rönninger Pharma Medicines Technical Operations Global Quality & Compliance,
More informationWhile the recognition
Designing the Perfect Change Control System Change control systems today are expected to be designed in a way that provides a system to not only document and approve changes, but also to anticipate change
More informationSchool of Pharmacy & Pharmaceutical Sciences QP Forum Thursday 16th April McGee Pharma International
School of Pharmacy & Pharmaceutical Sciences QP Forum Thursday 16th April 1 Parallel Session - Sterile Facilitator Ms Ann McGee 2 Query Topics Contamination Control Strategy Problems virtually managing
More informationData Integrity Why is it important? DADM Conference - 22 August 2017
Data Integrity Why is it important? DADM Conference - 22 August 2017 Maibritt Haugaard Møller, System Validation Expert Mette Ravn, Vice President, Data Management, IT and System Validation Overview of
More informationComputerised Systems. Inspection Expectations. Paul Moody, Inspector. 18/10/2013 Slide 1. ISPE GAMP COP Ireland Meeting, Dublin, 17 th October 2013
Computerised Systems Inspection Expectations ISPE GAMP COP Ireland Meeting, Dublin, 17 th October 2013 Paul Moody, Inspector Slide 1 Presentation Contents Brief Introduction to the IMB Regulatory References
More informationPlasma for Fractionation
www.pei.de Plasma for Fractionation Regulatory & Quality Standards in the EU Dr. Sabine Wegehaupt Inspection Services for Biological Medicinal Products IPFA Workshop Stellenbosch December 01-02, 2015 Plasma
More informationComments from: 1. General comments. International Plasma Fractionation Association (IPFA) Our ref. IP
Submission of comments on Commission proposal for Good Manufacturing Practice for Advanced Therapy Medicinal Products Comments from: Name of organisation or individual International
More informationICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective
ISPE Japan Affiliate 2016 Annual Meeting, April 14-15, 2016, Tower hall Funabori, Tokyo, Japan ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective Yasuhiro Kishioka, Ph.D. Principal
More information